Abstract: The invention provides a D-deoxyribose sugar for use in promoting wound healing wherein the sugar is provided in a carrier and wherein the carrier is a biocompatible matrix material or a hydrogel.

Abstract: The invention provides a D-deoxyribose sugar for use in promoting wound healing wherein the sugar is provided in a carrier and wherein the carrier is a biocompatible matrix material or a hydrogel.

Abstract: The present invention relates to a scaffold for the treatment of stress urinary incontinence, wherein the scaffold comprises three layers of polyurethane: a first layer and a third layer in which the polyurethane fibres are randomly orientated and a second layer between said first and third layers in which the fibres are aligned longitudinally; methods of making such scaffolds and uses thereof.

Abstract: Provided herein are methods for determining the chance of a tumor not responding to an anti-cancer therapy (e.g., a T cell-based immunotherapy) based on the presence, density, number, and/or location of certain three-cell structures as described herein. The three-cell structures may comprise a T cell, an immunosuppressive tumor-associated macrophage, and an immunosuppressive regulatory T cell. Such methods may be useful for identifying patients not likely to respond to T cell-based immunotherapy. Also provided herein are methods for determining the prognosis and/or invasiveness of a tumor. The present disclosure also encompasses methods for treating a tumor, as well as kits for performing the methods disclosed herein.

Abstract: Disclosed herein are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.

Abstract: This disclosure concerns transcription cassettes comprising nucleic acid molecules comprising a nucleotide sequence encoding AP-4 subunits; vectors comprising said transcription cassettes; pharmaceutical compositions comprising said vector; and vectors or compositions for use in the treatment of AP-4-Hereditary Spastic Paraplegia.

Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.

Abstract: The present disclosure relates to transcription cassettes comprising nucleic acids encoding RuvBL1 and/or RuvBL2 and the use of said vectors in gene therapy for the treatment of neurodegenerative diseases that result from expression of polymorphic repeat expansions of the GGGGCC (SEQ ID NO: 5) hexanucleotide-repeat sequence in the first intron of the C9ORF72 gene; pharmaceutical compositions comprising said vectors and including uses and methods to treat neurodegenerative diseases.

Abstract: The present invention relates to the modification of gene expression in plants in order to manipulate stomatal number, in particular to the modification of expression in plants of epidermal patterning factor (EPF). The invention also relates to genetically modified plants or plant parts with altered stomatal patterning compared to corresponding wild type plants or plant parts, where the plant stomatal development is altered by modification of the expression of EPF.

Abstract: Polyurethane material for indicating pH at a locus, preferably as indication of presence of microbes, comprising a polyurethane network having immobilised therein one or more hydrophilic copolymers, the or each said copolymer comprising: hydrophilic monomer; and indicating monomer, which provides an indication in response to a change in hydrophilic state of said hydrophilic monomer and/or copolymer; characterised in that the or each copolymer further comprises one or a plurality of ionisable groups or moieties or polymerisable monomers having one or more characteristic pKa values in the range 5 to 10 and which are responsive to pH at the locus in the range pH 5 to pH 10 and in that hydrophilic state of hydrophilic copolymer is dependent on ionisation of said ionisable groups, moieties or monomers; kit and device comprising the material and process for preparation thereof; and use in detecting or sensing microbes or pH.

Abstract: Device comprising polyurethane material for indicating pH at a locus, preferably as indication of presence of microbes, comprising a polyurethane network having immobilised therein one or more hydrophilic copolymers, the or each said copolymer comprising: hydrophilic monomer; and indicator monomer, which provides an indication in response to a change in hydrophilic state of said hydrophilic monomer and/or copolymer; characterised in that the or each copolymer further comprises one or a plurality of ionisable groups or moieties or polymerisable monomers having one or more characteristic pKa values in the range 5 to 10 and which are responsive to pH at the locus in the range pH 5 to pH 10 and in that hydrophilic state of hydrophilic copolymer is dependent on ionisation of said ionisable groups, moieties or monomers; kit and device comprising the material and process for preparation thereof; and use in detecting or sensing microbes or pH.

Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Abstract: The disclosure relates to long acting parathyroid or parathyroid hormone like fusion polypeptides comprising a receptor polypeptide and its use in the treatment of hypoparathyroidism and osteoporosis.

Abstract: The disclosure relates to long acting parathyroid or parathyroid hormone like fusion polypeptides comprising a receptor polypeptide and its use in the treatment of hypoparathyroidism and osteoporosis.

Abstract: A method for removing a hollow support element (17) from within a moulded part (15) to form a cavity (25) within the moulded part, the hollow support element being disposed within the moulded part and composed of material having a softening temperature, the method comprising: heating a liquid (20) to a temperature at least equal to the softening temperature of the material; injecting the heated liquid into an opening (24) in the moulded part to deform the material; and removing deformed material and liquid from the cavity.

Abstract: The present invention provides a polypeptide comprising an N-terminal polypeptide domain having luciferase activity and a C-terminal polypeptide domain having VAMP1, VAMP2 or VAMP3 activity where VAMP stands for vesicle-associated membrane protein. Corresponding nucleic acid molecules, expression vectors and genetically modified cells are also provided. The invention also provides methods and uses of the same.

Abstract: In an example, an avalanche photodiode comprises a substrate and a structure comprising a first layer and a second layer, the first and second layers over and parallel to the substrate, wherein the first layer is between the substrate and the second layer. The first layer is an Aluminium Arsenide Antimonide multiplication layer, and wherein the cross-sectional area parallel to the substrate of the first layer is smaller than that of the second layer, thereby forming a recess in a sidewall of the structure.

Abstract: This invention relates to an improved method for generating otic progenitor cells. The invention also relates to uses of such otic progenitor cells, for example as a medicament (e.g. in the treatment of hearing loss, deafness or other auditory disorder associated with loss of inner ear function) and/or in drug screening methods.

Abstract: The present disclosure relates to antagonists that target Serine/Arginine-Rich Splicing Factor 1 (SRSF1); expression vectors comprising SRSF1 antagonists; and the use of such antagonists in therapy for the treatment of neurodegenerative disorders and cancer and screening methods that identify agents that inhibit the expression or activity of SRSF1.

Abstract: A device for sensing and/or detecting species or stimulus at a locus, preferably at a fluid or moist locus by means of fluid communication therewith, comprising a surface configured to contact the locus, wherein the surface comprises a polyurethane material which material comprises a polyurethane polymer network having a hydrophilic polymer immobilised therein wherein the hydrophilic polymer comprises immobilised therein a ligand or moiety for detecting or sensing species or stimulus and an indicator for indicating detection or sensing prior to contact with the locus and change in indication as a function of species or stimulus present at the locus wherein species or stimulus are selected from chemical and biological species or stimulus; the use thereof preferably for detecting and/or sensing or binding bacteria, or for detecting or sensing pH or for detection or scanning with use of a reader; and a Kit.